KP Therapeutics (Europe)
First in Precision Medicine
About Us
Our Mission
At KP Therapeutics (Europe) our mission is to deliver innovations that change the face of healthcare. We do this by offering unique platform services in precision nanomedicine, and by advancing our own in-house pipeline programs through early-stage clinical development to early signs of efficacy for the treatment of cancers and other chronic diseases
Our Responsibility
KPT Europe is committed to the ethical principles and takes its responsibilities to the community very seriously.
Our company strives to develop innovative treatments, working to impact the outcomes that patients will value most. We understand that the true value of a medicine is in the difference it makes in a patients’ everyday lives.
KP Therapeutics (Europe) s.r.o (“KPT Europe”) was founded in July 2020 as a Bio Pharmaceutical company. We aim to become a global leader in the design and implementation of precision therapeutic approaches (PTAs) for the treatment of cancers and chronic diseases.
Our PTAs make use of proprietary precision nanomedicines and therapeutic agents either alone or in combination with clinically proven imaging and irradiation techniques. PTAs have the following basic elements; clear identification of target cells, guidance of therapeutics agents to target cells, and confirmation of therapeutic effects.
Our PTAs have the potential to revolutionise healthcare, disease treatments, change standards of clinical care, and transform the way patients are managed, ultimately improving and extending lives.
Meet the Team
Prof Andrew Miller
Chief Scientific Officer:
Nicholas G. A. Weaver
Managing Director
Publications
Publication Stand In
April 12, 2025
Publication Stand In
April 12, 2025
Publication Stand In
April 12, 2025
Contact Us
If you're interested in learning more about us, partnering with us, or working with us please do get in touch!